DE602005017373D1 - Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten - Google Patents
Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeitenInfo
- Publication number
- DE602005017373D1 DE602005017373D1 DE602005017373T DE602005017373T DE602005017373D1 DE 602005017373 D1 DE602005017373 D1 DE 602005017373D1 DE 602005017373 T DE602005017373 T DE 602005017373T DE 602005017373 T DE602005017373 T DE 602005017373T DE 602005017373 D1 DE602005017373 D1 DE 602005017373D1
- Authority
- DE
- Germany
- Prior art keywords
- gluco
- compounds
- treating schizophrenia
- regulatory conditions
- regulatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55845104P | 2004-04-01 | 2004-04-01 | |
PCT/US2005/011107 WO2005097122A2 (en) | 2004-04-01 | 2005-04-01 | Method of treating schizophrenia and/or glucoregulatory abnormalities |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602005017373D1 true DE602005017373D1 (de) | 2009-12-10 |
Family
ID=34978926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602005017373T Active DE602005017373D1 (de) | 2004-04-01 | 2005-04-01 | Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten |
Country Status (26)
Country | Link |
---|---|
US (1) | US20070129403A1 (de) |
EP (2) | EP2138176A1 (de) |
JP (1) | JP2007531730A (de) |
KR (1) | KR20070010161A (de) |
CN (1) | CN1946399A (de) |
AR (1) | AR048197A1 (de) |
AT (1) | ATE446754T1 (de) |
AU (1) | AU2005231446A1 (de) |
BR (1) | BRPI0509512A (de) |
CA (1) | CA2561162A1 (de) |
CL (1) | CL2009001605A1 (de) |
CY (1) | CY1109734T1 (de) |
DE (1) | DE602005017373D1 (de) |
DK (1) | DK1734959T3 (de) |
DO (1) | DOP2005000050A (de) |
ES (1) | ES2334241T3 (de) |
GT (1) | GT200500063A (de) |
IL (1) | IL178168A0 (de) |
MX (1) | MXPA06011222A (de) |
PA (1) | PA8628601A1 (de) |
PL (1) | PL1734959T3 (de) |
PT (1) | PT1734959E (de) |
SI (1) | SI1734959T1 (de) |
SV (1) | SV2006002069A (de) |
TW (1) | TW200602040A (de) |
WO (1) | WO2005097122A2 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
WO2008046049A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
WO2008060789A2 (en) | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
SG10201703086VA (en) | 2008-10-17 | 2017-05-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their use as therapeutic agents |
EP2350091B1 (de) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindol verbindungen und ihre verwendung als therapeutische wirkstoffe |
US20100152249A1 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of The Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
AU2010256541B2 (en) * | 2009-06-03 | 2016-03-10 | Marquette University | Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
RU2544852C2 (ru) | 2009-10-14 | 2015-03-20 | Ксенон Фармасьютикалз Инк. | Способы синтеза спиро-оксиндольных соединений |
US9504671B2 (en) | 2010-02-26 | 2016-11-29 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
CN103512972A (zh) * | 2013-07-29 | 2014-01-15 | 上海交通大学 | 精神***症的生物标志物及其使用方法和应用 |
TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
KR101759122B1 (ko) | 2015-08-07 | 2017-07-18 | 계명대학교 산학협력단 | 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물 |
JP6912574B2 (ja) | 2016-08-24 | 2021-08-04 | プリレニア ニューロセラピューティクス リミテッド | 機能低下を治療するためのプリドピジンの使用 |
CA3133876A1 (en) * | 2019-03-19 | 2020-09-24 | Cambridge Cognition Limited | Method and uses of diagnosing and recommending treatment for a psychotic disorder |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4970218A (en) | 1987-04-24 | 1990-11-13 | Hoechst-Roussel Pharmaceuticals Inc. | N-(pyridinyl)-1H-indol-1-amines |
US4880822A (en) * | 1987-04-24 | 1989-11-14 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyridinyl)-1H-indol-1-amines |
ATE115143T1 (de) * | 1987-04-24 | 1994-12-15 | Hoechst Roussel Pharma | N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel. |
US5102891A (en) * | 1990-07-23 | 1992-04-07 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates |
US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
US5356910A (en) * | 1993-07-19 | 1994-10-18 | Hoechst-Roussel Pharmaceuticals Inc. | Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder |
JP4189029B2 (ja) * | 1995-07-27 | 2008-12-03 | アベンティス・ファーマスーティカルズ・インコーポレイテッド | 抗けいれん剤としての未置換および置換n−(ピロール−1−イル)ピリジンアミンの使用 |
BR9707003A (pt) | 1996-01-17 | 1999-07-20 | Novo Nordisk As | Composto processos para preparar o mesmo para tratamento ou de prevenção de doenças do sistema endócrino e para a manufatura de medicamento coposção farmacêutica e utilização de um composto |
BRPI9711437B8 (pt) | 1996-08-30 | 2021-05-25 | Novo Nordisk As | derivados de glp-1 |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
EP1000066A1 (de) | 1997-07-16 | 2000-05-17 | Novo Nordisk A/S | Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung |
GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
-
2005
- 2005-03-22 GT GT200500063A patent/GT200500063A/es unknown
- 2005-03-30 DO DO2005000050A patent/DOP2005000050A/es unknown
- 2005-03-31 AR ARP050101275A patent/AR048197A1/es not_active Application Discontinuation
- 2005-04-01 AT AT05732721T patent/ATE446754T1/de not_active IP Right Cessation
- 2005-04-01 EP EP09012248A patent/EP2138176A1/de not_active Withdrawn
- 2005-04-01 PT PT05732721T patent/PT1734959E/pt unknown
- 2005-04-01 DK DK05732721.5T patent/DK1734959T3/da active
- 2005-04-01 EP EP05732721A patent/EP1734959B1/de not_active Not-in-force
- 2005-04-01 AU AU2005231446A patent/AU2005231446A1/en not_active Abandoned
- 2005-04-01 ES ES05732721T patent/ES2334241T3/es active Active
- 2005-04-01 TW TW094110410A patent/TW200602040A/zh unknown
- 2005-04-01 CA CA002561162A patent/CA2561162A1/en not_active Abandoned
- 2005-04-01 MX MXPA06011222A patent/MXPA06011222A/es active IP Right Grant
- 2005-04-01 DE DE602005017373T patent/DE602005017373D1/de active Active
- 2005-04-01 PL PL05732721T patent/PL1734959T3/pl unknown
- 2005-04-01 JP JP2007506313A patent/JP2007531730A/ja not_active Abandoned
- 2005-04-01 SV SV2005002069A patent/SV2006002069A/es unknown
- 2005-04-01 SI SI200530883T patent/SI1734959T1/sl unknown
- 2005-04-01 CN CNA2005800121147A patent/CN1946399A/zh active Pending
- 2005-04-01 PA PA20058628601A patent/PA8628601A1/es unknown
- 2005-04-01 BR BRPI0509512-3A patent/BRPI0509512A/pt not_active IP Right Cessation
- 2005-04-01 WO PCT/US2005/011107 patent/WO2005097122A2/en active Application Filing
- 2005-04-01 KR KR1020067022972A patent/KR20070010161A/ko not_active Application Discontinuation
-
2006
- 2006-09-18 IL IL178168A patent/IL178168A0/en unknown
- 2006-09-29 US US11/536,808 patent/US20070129403A1/en not_active Abandoned
-
2009
- 2009-07-17 CL CL2009001605A patent/CL2009001605A1/es unknown
-
2010
- 2010-01-11 CY CY20101100028T patent/CY1109734T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ATE446754T1 (de) | 2009-11-15 |
DOP2005000050A (es) | 2005-11-30 |
EP2138176A1 (de) | 2009-12-30 |
GT200500063A (es) | 2005-10-14 |
PL1734959T3 (pl) | 2010-03-31 |
CA2561162A1 (en) | 2005-10-20 |
AU2005231446A1 (en) | 2005-10-20 |
DK1734959T3 (da) | 2010-03-08 |
US20070129403A1 (en) | 2007-06-07 |
KR20070010161A (ko) | 2007-01-22 |
PT1734959E (pt) | 2009-12-24 |
WO2005097122A2 (en) | 2005-10-20 |
CN1946399A (zh) | 2007-04-11 |
ES2334241T3 (es) | 2010-03-08 |
IL178168A0 (en) | 2006-12-31 |
MXPA06011222A (es) | 2007-01-16 |
CY1109734T1 (el) | 2014-09-10 |
PA8628601A1 (es) | 2006-05-16 |
EP1734959A2 (de) | 2006-12-27 |
BRPI0509512A (pt) | 2007-09-11 |
JP2007531730A (ja) | 2007-11-08 |
WO2005097122A3 (en) | 2006-02-02 |
SV2006002069A (es) | 2006-05-24 |
AR048197A1 (es) | 2006-04-05 |
EP1734959B1 (de) | 2009-10-28 |
CL2009001605A1 (es) | 2009-11-27 |
SI1734959T1 (sl) | 2010-02-26 |
TW200602040A (en) | 2006-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602005017373D1 (de) | Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten | |
ATE489955T1 (de) | Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten | |
DE602007006479D1 (de) | Verfahren und vorrichtungen zur behandlung von mehreren bohrlochintervallen | |
ATE515261T1 (de) | Zusammensetzungen zur behandlung von diabetes | |
DE602005026984D1 (de) | Chinolin-derivate zur behandlung von latenter tuberkulose | |
ATE554091T1 (de) | Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes | |
DE602006019560D1 (de) | 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen | |
ATE509615T1 (de) | Verfahren und zusammensetzungen zur verhütung und/oder zur behandlung von empfindlicher und/oder trockener haut | |
ATE496911T3 (de) | Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten | |
DE602006006354D1 (de) | Pinolensäure zur Behandlung von Übergewicht | |
DE602005007717D1 (de) | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen | |
ATE550338T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
DE502005010499D1 (de) | Implantat zur Behandlung von Fettsucht | |
DE602006020201D1 (de) | Aerobes-anaerobes Verfahren zur Behandlung von organisch belasteten Abwässern | |
DE602006003538D1 (de) | Benzothiazol-, thiazolopyridin-, benzooxazol- und oxazolopyridin-derivate als verbindungen zur behandlung von diabetes | |
DE602005023452D1 (de) | Mit calcitriol und clobetasolpropionat zur behandlung von schuppenflechte | |
DE602006017367D1 (de) | Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut | |
DE602004010705D1 (de) | Vorrichtung und Verfahren zur Behandlung von Mist enthaltendem Abwasser | |
DE602005010222D1 (de) | Verwendung eines phenothiazin-derivats zur prävention und/oder behandlung von gerhörverlust | |
DE60321938D1 (de) | Zusammensetzung zur schleimvermeidung und verfahren zur schleimvermeidung | |
DE602006003094D1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit | |
ATE439843T1 (de) | S-mirtazapin zur behandlung von hitzewallungen | |
DE602004021435D1 (de) | Injizierbare zusammensetzung zur behandlung von krebs | |
DE602006021192D1 (de) | Visnadin zur Behandlung von Kopfhautjucken | |
DE602004022153D1 (de) | Verbindungen zur behandlung von obesitas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |